四川雙馬(000935.SZ)控股子公司湖北健翔通過美國FDA現場檢查
格隆匯12月8日丨四川雙馬(000935.SZ)發佈公吿,近日,湖北健翔收到美國FDA出具的現場核查報吿(Establishment Inspection Report),根據該核查報吿,湖北健翔的質量和生產體系等均符合美國FDA的標準,湖北健翔通過了美國FDA現場檢查。
本次順利通過美國FDA現場檢查,標誌着公司原料藥生產基地湖北健翔在質量管理體系和生產環境設施等方面符合美國FDA要求。這不僅為公司在美國市場的業務持續發展提供了堅實的基礎,也增強了公司在國際市場上的影響力,對未來經營業績具有積極影響。湖北健翔完善和高效的原料藥生產體系和管理體系,將助力公司提升綜合競爭力,為公司的長遠發展注入動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.